Eli Lilly’s weight loss jab Mounjaro leads to faster and greater weight loss than Novo Nordisk’s versions Wegovy and Ozempic, a new study demonstrates.
Latest research has found that 42.3% of people using Mounjaro lost at least 15% of their weight within a year of using the weight loss injection, which contains tirzepatide.
Meanwhile, only 19.3% of individuals using Wegovy or Ozempic which contains semaglutide, lost at least 15% of their weight, the study has reported.
- Mounjaro: new weight loss jab approved in the UK
- Mounjaro may soon be approved by NHS for weight loss
- Warning that Ozempic and Mounjaro can trigger accelerated aging
According to the results, Mounjaro users were three times more likely to lose at least 15% of their body weight compared to Ozempic users.
During the study, the team of researchers analysed the health data of 9,193 adults using Mounjaro and the same number of people using Ozempic.
Approximately 50% of the participants had type 2 diabetes and the average person involved in the trial weighed 17 stones 4 lbs.
The researchers found that after three months of using the weight loss jabs, those on Mounjaro had lost an average of 2.3% more body weight than those taking Ozempic.
By 12 months, the Mounjaro users had lost an average of 7.2% more weight than the Ozempic users.
A spokesperson from Eli Lilly has said: “The company does not promote or encourage the off-label use of its medicines, although its drug is now approved for weight loss.”
- Weight loss: people more likely to join programmes if GPs use positive language
- Woman suffers fatal intestine blockages after using weight-loss jab
- FDA approves new obesity drug Zepbound to compete with Wegovy
Novo Nordisk has stated: “The doses of semaglutide evaluated in this analysis have not been investigated for chronic weight management, and there are no head-to-head trials that have (been) reported which evaluate Wegovy and tirzepatide.
“This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.”
